NO984082D0 - Pyrimido£5,4-d|pyrimidiner, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmÕte for fremstilling derav - Google Patents
Pyrimido£5,4-d|pyrimidiner, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmÕte for fremstilling deravInfo
- Publication number
- NO984082D0 NO984082D0 NO984082A NO984082A NO984082D0 NO 984082 D0 NO984082 D0 NO 984082D0 NO 984082 A NO984082 A NO 984082A NO 984082 A NO984082 A NO 984082A NO 984082 D0 NO984082 D0 NO 984082D0
- Authority
- NO
- Norway
- Prior art keywords
- pyrimido
- pyrimidines
- compounds
- preparation
- drugs containing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19608588A DE19608588A1 (de) | 1996-03-06 | 1996-03-06 | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
PCT/EP1997/001047 WO1997032880A1 (de) | 1996-03-06 | 1997-03-03 | PYRIMIDO[5,4-d]PYRIMIDINE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL, DEREN VERWENDUNG UND VERFAHREN ZU IHRER HERSTELLUNG |
Publications (3)
Publication Number | Publication Date |
---|---|
NO984082L NO984082L (no) | 1998-09-04 |
NO984082D0 true NO984082D0 (no) | 1998-09-04 |
NO311522B1 NO311522B1 (no) | 2001-12-03 |
Family
ID=7787345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19984082A NO311522B1 (no) | 1996-03-06 | 1998-09-04 | Pyrimido[5,4-d]pyrimidiner, legemiddel inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstillingderav |
Country Status (30)
Country | Link |
---|---|
US (1) | US5821240A (no) |
EP (1) | EP0888351B1 (no) |
JP (1) | JP2000506151A (no) |
KR (1) | KR19990087504A (no) |
CN (1) | CN1064362C (no) |
AR (1) | AR006108A1 (no) |
AT (1) | ATE252101T1 (no) |
AU (1) | AU730376B2 (no) |
BG (1) | BG63163B1 (no) |
BR (1) | BR9707839A (no) |
CA (1) | CA2248720A1 (no) |
CO (1) | CO4650043A1 (no) |
CZ (1) | CZ281598A3 (no) |
DE (2) | DE19608588A1 (no) |
EE (1) | EE9800278A (no) |
HK (1) | HK1018450A1 (no) |
HU (1) | HUP9902049A3 (no) |
IL (1) | IL125342A0 (no) |
MX (1) | MX9807073A (no) |
NO (1) | NO311522B1 (no) |
NZ (1) | NZ331545A (no) |
PL (1) | PL328719A1 (no) |
RU (1) | RU2195461C2 (no) |
SK (1) | SK120898A3 (no) |
TR (1) | TR199801755T2 (no) |
TW (1) | TW454008B (no) |
UA (1) | UA54421C2 (no) |
UY (1) | UY24474A1 (no) |
WO (1) | WO1997032880A1 (no) |
ZA (1) | ZA971887B (no) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR199801530T2 (xx) | 1996-02-13 | 1998-11-23 | Zeneca Limited | VEGF �nhibit�rleri olarak kinazolin t�revleri. |
JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | 4―アニリノキナゾリン誘導体 |
US6028183A (en) | 1997-11-07 | 2000-02-22 | Gilead Sciences, Inc. | Pyrimidine derivatives and oligonucleotides containing same |
JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
UA72946C2 (uk) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
EP1170011A1 (en) * | 2000-07-06 | 2002-01-09 | Boehringer Ingelheim International GmbH | Novel use of inhibitors of the epidermal growth factor receptor |
DE10115921A1 (de) | 2001-03-30 | 2002-10-02 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von 4,6-Diaminopyrimido[5,4-d]pyrimidinen |
EP1300146A1 (en) * | 2001-10-03 | 2003-04-09 | Boehringer Ingelheim International GmbH | Pharmaceutical composition for the treatment of animal mammary tumors |
EP1460061A4 (en) * | 2001-12-27 | 2006-05-31 | Toray Finechemicals Co Ltd | PROCESS FOR PRODUCING 1-ALCOXYCARBONYL SATURATED NITROGENIC HETEROCYCLIC DERIVATIVE |
US20070179161A1 (en) * | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
EA013904B1 (ru) * | 2003-12-18 | 2010-08-30 | Янссен Фармацевтика Н.В. | Пиридо- и пиримидопиримидиновые производные в качестве антипролиферативных агентов |
JO3088B1 (ar) * | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
KR101139038B1 (ko) * | 2005-06-28 | 2012-05-02 | 삼성전자주식회사 | 피리미도피리미딘 유도체 및 이를 이용한 유기 박막 트랜지스터 |
EP2044084B1 (en) | 2006-07-13 | 2016-02-17 | Janssen Pharmaceutica NV | Mtki quinazoline derivatives |
ES2435454T3 (es) * | 2007-06-21 | 2013-12-19 | Janssen Pharmaceutica, N.V. | Indolin-2-onas y aza-indolin-2-onas |
GB0713602D0 (en) * | 2007-07-12 | 2007-08-22 | Syngenta Participations Ag | Chemical compounds |
JP5536647B2 (ja) | 2007-07-27 | 2014-07-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピロロピリミジン |
JP2009215259A (ja) * | 2008-03-12 | 2009-09-24 | Ube Ind Ltd | 3−ハロゲノ−4−ヒドロカルビルオキシニトロベンゼン化合物の製造方法 |
AR073501A1 (es) * | 2008-09-08 | 2010-11-10 | Boehringer Ingelheim Int | Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa |
WO2010054264A1 (en) | 2008-11-07 | 2010-05-14 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
WO2010094695A1 (en) | 2009-02-17 | 2010-08-26 | Boehringer Ingelheim International Gmbh | Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2010099137A2 (en) | 2009-02-26 | 2010-09-02 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the emt status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US20120064072A1 (en) | 2009-03-18 | 2012-03-15 | Maryland Franklin | Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor |
US20120316187A1 (en) | 2009-11-13 | 2012-12-13 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
JP6297490B2 (ja) | 2011-08-31 | 2018-03-20 | ジェネンテック, インコーポレイテッド | 診断マーカー |
WO2013055530A1 (en) | 2011-09-30 | 2013-04-18 | Genentech, Inc. | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
WO2014134202A1 (en) | 2013-02-26 | 2014-09-04 | Triact Therapeutics, Inc. | Cancer therapy |
EP2976085A1 (en) | 2013-03-21 | 2016-01-27 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
MX2017008421A (es) | 2014-12-24 | 2018-03-23 | Genentech Inc | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. |
RS62456B1 (sr) | 2016-12-22 | 2021-11-30 | Amgen Inc | Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
SG11202001499WA (en) | 2017-09-08 | 2020-03-30 | Amgen Inc | Inhibitors of kras g12c and methods of using the same |
EP3788038B1 (en) | 2018-05-04 | 2023-10-11 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
US11045484B2 (en) | 2018-05-04 | 2021-06-29 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
WO2019217691A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
US11096939B2 (en) | 2018-06-01 | 2021-08-24 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
EP3802537A1 (en) | 2018-06-11 | 2021-04-14 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
MX2020012261A (es) | 2018-06-12 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. |
US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
CA3117222A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
PE20211475A1 (es) | 2018-12-20 | 2021-08-05 | Amgen Inc | Inhibidores de kif18a |
ES2953821T3 (es) | 2018-12-20 | 2023-11-16 | Amgen Inc | Inhibidores de KIF18A |
MA54547A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
MA54546A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
US20230096028A1 (en) | 2019-03-01 | 2023-03-30 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
JP2022522777A (ja) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
EP3972973A1 (en) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
CN114401953A (zh) | 2019-08-02 | 2022-04-26 | 美国安进公司 | Kif18a抑制剂 |
US20220372018A1 (en) | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
WO2021026098A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
AU2020324963A1 (en) | 2019-08-02 | 2022-02-24 | Amgen Inc. | KIF18A inhibitors |
WO2021081212A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
CA3159559A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
TW202132314A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras抑制劑 |
EP4054719A1 (en) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
PE20230249A1 (es) | 2019-11-08 | 2023-02-07 | Revolution Medicines Inc | Compuestos de heteroarilo biciclicos y usos de estos |
WO2021097212A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
AR120456A1 (es) | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ras阻害剤及びその使用 |
BR112022010086A2 (pt) | 2020-01-07 | 2022-09-06 | Revolution Medicines Inc | Dosagem do inibidor de shp2 e métodos de tratamento de câncer |
CN115052878A (zh) | 2020-02-03 | 2022-09-13 | 勃林格殷格翰国际有限公司 | 作为HER2抑制剂的[1,3]二嗪并[5,4-d]嘧啶 |
CN115052881A (zh) | 2020-02-03 | 2022-09-13 | 勃林格殷格翰国际有限公司 | 作为HER2抑制剂的[1,3]二嗪并[5,4-d]嘧啶 |
US11608343B2 (en) * | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
KR20230067635A (ko) | 2020-09-15 | 2023-05-16 | 레볼루션 메디슨즈, 인크. | 암의 치료에서 ras 억제제로서 인돌 유도체 |
CN117396472A (zh) | 2020-12-22 | 2024-01-12 | 上海齐鲁锐格医药研发有限公司 | Sos1抑制剂及其用途 |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
CR20230570A (es) | 2021-05-05 | 2024-01-22 | Revolution Medicines Inc | Inhibidores de ras |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3049207A1 (de) * | 1980-12-27 | 1982-07-29 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue trisubstituierte pyrimido (5,4-d) pyrimidine, ihre herstellung und ihre verwendung als arzneimittel |
TW414798B (en) * | 1994-09-07 | 2000-12-11 | Thomae Gmbh Dr K | Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation |
DE4431867A1 (de) * | 1994-09-07 | 1996-03-14 | Thomae Gmbh Dr K | Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
-
1996
- 1996-03-06 DE DE19608588A patent/DE19608588A1/de not_active Ceased
-
1997
- 1997-02-28 UY UY24474A patent/UY24474A1/es not_active Application Discontinuation
- 1997-03-03 NZ NZ331545A patent/NZ331545A/xx unknown
- 1997-03-03 KR KR1019980706935A patent/KR19990087504A/ko not_active Application Discontinuation
- 1997-03-03 DE DE59710864T patent/DE59710864D1/de not_active Expired - Fee Related
- 1997-03-03 IL IL12534297A patent/IL125342A0/xx unknown
- 1997-03-03 SK SK1208-98A patent/SK120898A3/sk unknown
- 1997-03-03 EP EP97906152A patent/EP0888351B1/de not_active Expired - Lifetime
- 1997-03-03 HU HU9902049A patent/HUP9902049A3/hu not_active Application Discontinuation
- 1997-03-03 RU RU98118380/04A patent/RU2195461C2/ru not_active IP Right Cessation
- 1997-03-03 AU AU20945/97A patent/AU730376B2/en not_active Ceased
- 1997-03-03 JP JP9531440A patent/JP2000506151A/ja not_active Ceased
- 1997-03-03 PL PL97328719A patent/PL328719A1/xx unknown
- 1997-03-03 EE EE9800278A patent/EE9800278A/xx unknown
- 1997-03-03 UA UA98105276A patent/UA54421C2/uk unknown
- 1997-03-03 AT AT97906152T patent/ATE252101T1/de not_active IP Right Cessation
- 1997-03-03 CA CA002248720A patent/CA2248720A1/en not_active Abandoned
- 1997-03-03 CN CN97192784A patent/CN1064362C/zh not_active Expired - Fee Related
- 1997-03-03 TR TR1998/01755T patent/TR199801755T2/xx unknown
- 1997-03-03 BR BR9707839A patent/BR9707839A/pt not_active Application Discontinuation
- 1997-03-03 CZ CZ982815A patent/CZ281598A3/cs unknown
- 1997-03-03 WO PCT/EP1997/001047 patent/WO1997032880A1/de not_active Application Discontinuation
- 1997-03-05 ZA ZA971887A patent/ZA971887B/xx unknown
- 1997-03-05 US US08/811,907 patent/US5821240A/en not_active Expired - Lifetime
- 1997-03-05 AR ARP970100873A patent/AR006108A1/es unknown
- 1997-03-06 TW TW086102755A patent/TW454008B/zh not_active IP Right Cessation
- 1997-03-06 CO CO97012277A patent/CO4650043A1/es unknown
-
1998
- 1998-08-31 MX MX9807073A patent/MX9807073A/es not_active IP Right Cessation
- 1998-09-04 NO NO19984082A patent/NO311522B1/no not_active IP Right Cessation
- 1998-09-24 BG BG102789A patent/BG63163B1/bg unknown
-
1999
- 1999-08-10 HK HK99103458A patent/HK1018450A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO984082D0 (no) | Pyrimido£5,4-d|pyrimidiner, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmÕte for fremstilling derav | |
NO984081D0 (no) | Pyrimido£5,4-d|pyrimidiner, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmÕte for fremtilling derav | |
NO974151D0 (no) | 6-substituerte pyrazolo (3,4-d) pyrimidin-4-oner og preparater og fremgangsmåter for anvendelse derav | |
HUP0001140A3 (en) | Substituted pyrimidinone and pyridone compounds and methods of use | |
EE04193B1 (et) | Triasolo[4,5-d]pürimidiini ühendid, neid sisaldavad ravimkoostised ja nende valmistamise meetodid | |
NO984084D0 (no) | 4-Amino-pyrimidin-derivater, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmÕte ved fremstilling derav | |
PL327532A1 (en) | Derivatives of 5h-thiazole[3,2-a]pyrimidine, method of obtaining them and medicine containing such derivatives | |
NO942196D0 (no) | Fluorenforbindelser og fremgangsmåte for deres fremstilling | |
HUP0100202A3 (en) | Novel triazolo[4,5-d]pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
DK1015444T3 (da) | Pyrimidinderivater og fremgangsmåder til fremstilling deraf | |
NO996043L (no) | 3-Substituerte 3,4-dihydro-tieno[2,3-d]pyrimidin derivater, deres fremstilling og anvendelse | |
NO20003067D0 (no) | Antipicornavirus-forbindelser og fremgangsmÕter for deres anvendelse og fremstilling | |
NO974150D0 (no) | 6-arylpyrazolo(3,4-d)pyrimidin-4-oner og preparater og fremgangsmåter for anvendelse derav | |
DK0927184T3 (da) | 3-substituerede pyrido[4',3':4,5]thieno-[2,3-d]pyrimidinderivater, deres fremstilling og anvendelse | |
DE69633503D1 (de) | 1,2,4- triazolo (4,3-b) pyridazinderivate und ihre verwendung | |
DK122587A (da) | Pyrazolo(3,4-d)pyrimidinderivater og fremstilling og anvendelse deraf | |
IL150163A (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND SOME NOVEL SUCH COMPOUNDS | |
NO996045L (no) | 3-Substituerte pyrido[3',4':4,5]tieno[2,3-d]pyrimidin- derivater, fremstilling og anvendelse derav | |
ZA9710911B (en) | Substituted pyrimidinone and pyridone compounds and methods of use. | |
KR970705564A (ko) | 피리미도[5,4-d]피리미딘, 이를 포함하는 약제, 이의 용도 및 이의 제조 방법(Pyrimido[5,4-d]pyrimidines, drugs containing these compounds, their use, and process for preparing them) | |
PL303357A1 (en) | Novel derivative of isothiasolo [5,4-d] pyrimidine | |
PL303358A1 (en) | Novel derivative of isothiasolo [5,4-d] pyrimidine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |